We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

September 17, 2021

September HealthXL Meeting Snapshot

Commentary
HealthXL Team & HealthXL Community
&

Our meetings create a space for industry experts to connect and discuss the most current and evolving topics in the digital health space. This segment highlights key learnings and ideas cultivated by our network of payers, providers, pharmaceutical companies, health care and technology organizations.

DTx Opportunity for Pharmaceutical Companies - August 11th, 2021

Pharma companies are accelerating their incorporation of digital tools across all aspects of their business with Digital Therapeutics (DTx) being an element of this digital transformation. However, what DTx means in practice for Pharma companies is still primarily pilots as companies grapple to see how to monetize DTx in a traditional pharma business. 


So far, most pharma-DTx collaborations have been companion-style DTx as opposed to standalone therapies. Pharma is beginning to explore the digital opportunity a lot more, to the point of considering standalone digital revenue models. For the foreseeable future, however, the focus will continue to be predominantly on digital companions. 


From an organizational perspective, pharma companies may need to increase internal education to better understand the real value of digital companion and DTx. This education is often lacking and can lead to budget hopping which presents a big issue. Pharmaceutical companies are large and complex organizations which DTx vendors (especially startups) need to learn how to navigate. In partnership talks, it might well be the startup that needs to ensure the right pharma stakeholders are in the conversation.


At present, pharma partnerships stand to benefit the DTx vendor more so than the pharma partner. A lot of DTx partnerships have been signed with the promise of future rewards; however, long production cycles and the protracted process of achieving scale mean that the promise cannot be achieved immediately and may require more time than originally anticipated. Learning from these partnerships has changed pharma behavior who are becoming more risk aware and realistic in terms of expectations.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Measuring Efficacy and Safety of DTx - August 24th, 2021

There are a broad number of DTx solutions, but in order to thrive and be successfully adopted, prescribed and reimbursed, it is essential to prove their efficacy and safety. The various stakeholders/gatekeepers in the pathway to getting a DTx to a patient have differing expectations and requests for "evidence" based on this data, such that DTx developers can be in a goalpost shifting world as they attempt to get approval for their solution. This is particularly the case in relation to reimbursement approval - in its broadest sense. There is an opportunity and need for standardization around expectations of evidence from key stakeholders in the delivery of digital therapeutics to patients. In essence we need better clarity on what should be measured. 


There are also considerations as to how it should be measured, be it RCTs or RWE. DTx companies have faced challenges to performing RCTs such as cost, time, and constantly evolving software/devices. Therefore distinctions between a RCT vs a RWE trial may not be the most appropriate place to start the discussion on how to measure safety and efficacy of digital therapeutics. Well executed trials with appropriate registration and transparency on how trials were designed and executed is an obvious starting point. Incorporating data from a variety of sources to best illustrate the clinical and economic efficacy of a DTx can mean data that would look more at home in a traditional RCT as well as other data that looks more like a RWE trail co-existing in the framework of a single trail. There will be a need for professionals from a HEOR and clinical development backgrounds coming together to solve this. A key part of the solution will be doing these studies in much more efficient ways.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Digital Health and US Patient Access Rule: Opportunities for innovators - August 31st, 2021

The new CMS Interoperability and Patient Access final rule puts patients first by giving them access to their health information. The new ruling requires certain payers to make a Patient Access API available for patients to access their health data and to exchange it with 3rd party applications. Patient data will now be consistently leaving covered entities under the scope of HIPAA and into the scope of the Federal Trade Commission (FTC). For the first time, consumer facing applications, like digital health tools, now have the opportunity to access this data from payers on behalf of patients. 


Patients can give consent to 3rd parties to retrieve data held on them by specified payers/health plans. Features include access to claims data, clinical data, a provider directory API, a formulary directory API and a developer portal. While there is a lot of data, it does not automatically include all EHR data meaning there will be gaps, making it difficult to create a problem list for the patient from this data alone. Comprehensive patient data requests require manual efforts and until EHR vendors streamline their data capture and arrangement it will still require quite a bit of effort to clean up this data - having 8 ways to schedule an appointment in one EHR system does not help.


Digital health companies can use this additional data to expand or improve their offering to provide a broader range of services to patients. Designing the interface for patients to provide enough detail to build trust while at the same time minimizing friction for users will be essential to getting buy-in and utilization. The "why" in this for patients needs to be clear for them to go through the bother of sharing this data.

Want to join the conversation? Check out our website for upcoming meetings and events!

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The New Reimbursement Path for Digital Health in Belgium

27th September @ 10AM GMT/5PM AWST

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

27th September @ 10:45AM EDT

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

28th September @ 10AM GMT / 5PM AWST

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

What are the Best Business Models for DTx in the US?

4th October @ 10:45AM EDT

What are the best models for DTx in the US in this new reality? How will the business models change in the future? Join us in a peer-to-peer conversation where we will discuss these questions and more!

Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics
Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
27th September @ 10AM GMT/5PM AWST

Masterclass: The New Reimbursement Path for Digital Health in Belgium

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Steven Vandeput, PhD
Featuring
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
27th September @ 10:45AM EDT

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Stephen Gibney
Featuring
Stephen Gibney
Quality Director, BlueBridge Technologies
Telemedicine & Virtual Care Delivery
28th September @ 10:45AM EDT

What Will the Best Business Models Be for Virtual Care in Diabetes?

Join this meeting to take a deep dive into what the best business models will be in the next few years for virtual care companies in the diabetes space.

Frank Westermann
Featuring
Frank Westermann
Co-Founder & Co-CEO, 9am.health
Digital Therapeutics (DTx)
28th September @ 10AM GMT / 5PM AWST

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Eugene Borukhovich
Featuring
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.